Boiron Action

Boiron EBITDA

EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) de Boiron (BOI.PA) au 5 août 2026 est 36,60 M EUR. L'année précédente, EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) était 21,07 M EUR — une variation de 73,74 % (plus élevé).

EBITDA

36,60 MEUR

YoY

73,74%

Dernière mise à jour:

EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) de Boiron est 2026 36,60 M EUR. EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) de Boiron était 2025 21,07 M EUR. Elle diminue ainsi de 73,74% plus élevé par rapport à l'année précédente.
Access this data via the Eulerpool API

Boiron Analyse d'actions

Que fait Boiron ? Boiron SA is a French company specializing in the production of homeopathic medicines. It was founded in 1932 by the Boiron brothers Jean and Henri and is headquartered in Lyon, France. Boiron SA is now a global leader in the production of medicines based on natural ingredients. The business model of Boiron SA is based on the production and marketing of homeopathic medicines. These are made from plant, animal, and mineral raw materials and are intended to help with a variety of symptoms and illnesses. Homeopathic remedies are made based on the teachings of German physician Samuel Hahnemann, who founded homeopathy as an alternative healing method in the 18th century. Homeopathy assumes that similar things have similar effects. So if a substance causes specific symptoms in a healthy person, it is supposed to help a sick person with similar symptoms. Homeopathic remedies are usually low in side effects and can also be used in children and pregnant women. Boiron SA is divided into different divisions, each responsible for different areas and symptoms. One of the most important divisions is "General Medicine," which offers homeopathic medicines for a variety of symptoms, including colds, headaches, gastrointestinal problems, and injuries. The "Pediatrics" division offers homeopathic remedies specifically for children, including teething problems, sleep disorders, and hyperactivity. Another important division is "Women's Medicine," which offers homeopathic medicines for gynecological complaints and menstrual problems. Boiron SA also offers homeopathic medicines for animals that can be used for various complaints. Boiron SA has a wide range of homeopathic medicines available, including globules, tablets, drops, ointments, and suppositories. There are also homeopathic medicines in the form of sprays and eye drops that can be used for allergic reactions and respiratory diseases. Boiron SA is continuously developing new homeopathic remedies and improving existing ones to increase their effectiveness and quality. Boiron SA is headquartered in Lyon and is represented in over 50 countries. The company manufactures its homeopathic medicines and distributes them through pharmacies, drugstores, and online shops. Boiron SA also has its own pharmacies in various countries, including Germany, France, and Spain, where homeopathic remedies and other natural remedies are sold. In recent years, Boiron SA has attracted public criticism due to the controversial effectiveness of homeopathic remedies. Critics of homeopathy argue that its effects are based on placebo effects and that there is no scientific evidence of effectiveness. Boiron SA defends its homeopathic medicines and refers to numerous studies and patient experiences that are convinced of their effectiveness. Boiron SA is a successful company specializing in the production of homeopathic medicines. It offers a wide range of homeopathic remedies for various symptoms and is headquartered in Lyon, France. Although homeopathy is controversial, Boiron SA defends its products and advocates for broader recognition of homeopathic remedies. Boiron est l'une des entreprises les plus populaires sur Eulerpool.

Questions fréquemment posées sur l'action Boiron

EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) de Boiron s'élève à 36,60 M EUR en 2026.

EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) de Boiron a changé de 21,07 M EUR à 36,60 M EUR, ce qui représente une variation de 73,74 %. La valeur est plus élevé qu'l'année précédente.

Sur Eulerpool, vous trouverez l'évolution historique complète de Boiron de EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) depuis 2006 – avec des valeurs annuelles, des graphiques et une analyse détaillée.

L'EBITDA mesure la performance opérationnelle avant l'impact de la structure financière, de l'environnement fiscal et des charges de dépréciation non monétaires.

EBITDA = EBIT + Dépréciations et amortissements

EUR de EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) est un facteur clé pour les investisseurs. Les changements dans cette métrique peuvent signaler une amélioration ou une détérioration des fondamentaux, impactant directement le cours de l'action. Sur Eulerpool, vous pouvez suivre Boiron de EBITDA (Résultat avant intérêts, impôts, amortissements et dépréciations) historiquement et en temps réel.

Access this data via the Eulerpool API

Compte de résultat — Boiron

Toutes les Métriques Clés — Boiron

Croissance